Head to head
Si-Bone vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: SIBN · ABT
SIBN
Si-Bone
18.68-2.20%
1-year price shape — +25% over the period
Quant Rating B · 72/100
vs
ABT
Abbott Laboratories
97.43-1.32%
1-year price shape — -24% over the period
Quant Rating E · 15/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories pays the highest dividend yield; Abbott Laboratories earns the most per share.
| SIBN | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Devices | Medical Devices |
| Last price | 18.68 | 97.43 |
| Change today | -2.20% | -1.32% |
| 1-year return | +24.6% | -24.1% |
| Market cap | $837.21M | $168.59B |
| 52-week range | 11.48 – 21.89 | 81.39 – 130.33 |
| Valuation | ||
| P/E (TTM) | -56.61 | 31.53 |
| P/E percentile, own 5-yr range | 1st | 62nd |
| P/B | 4.59 | 3.30 |
| Dividend yield | 0.00% | 2.50% |
| Profitability & growth | ||
| EPS (TTM) | -0.44 | 3.72 |
| Net profit (TTM) | $-19.72M | $6.44B |
| Revenue (TTM) | $213.60M | $46.59B |
| Revenue growth (YoY) | +15.2% | +13.0% |
| Gross margin | 79.5% | 56.6% |
| Operating margin | -8.3% | 15.8% |
| Net margin | -6.9% | 11.6% |
| Free cash flow (TTM) | $-4.39M | $7.82B |
| Ownership & sentiment | ||
| Institutional ownership | 109.5% | 81.2% |
| Insider activity (12mo) | 13 buy / 37 sell | 36 buy / 12 sell |
| Short interest (% of float) | 13.2% | 1.1% |
| Analyst consensus | 100% buy (7) | 100% buy (14) |
| Analyst price target | $25 (+31%) | $125 (+28%) |
| StockVane view | ||
| StockVane Quant Rating | B (72) | E (15) |
| Company | ||
| Employees | 559 | 115,000 |
| Founded | 2008 | 1888 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.